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Abstract
Objectives Chronic obstructive pulmonary disease (COPD) is a progressive
chronic condition that can be effectively managed by smoking-cessation, optimising
prescribed therapy and providing treatment to prevent chest infections from causing
hospitalisation. The government agenda in the UK is for community pharmacists to
become involved in chronic disease management, and COPD is one area where they
are ideally located to provide a comprehensive service.
This study aims to evaluate the effect of a community pharmacy–based COPD
service on patient outcomes.
Methods Patients in one UK location were recruited over a 10-week period to
receive a community pharmacy–based COPD support service consisting of sign-
posting to or provision of smoking-cessation service, therapy optimisation and rec-
ommendation to obtain a rescue pack containing steroid and antibiotic to prevent
hospitalisation as a result of chest infection. Data were collected over a 6-month
period for all recruited patients. Appropriate clinical outcomes, patient reported
medication adherence, quality of life and National Health Service (NHS) resource
utilisation were measured.
Key findings Three hundred six patients accessed the service. Data to enable com-
parison before and after intervention was available for 137 patients. Significant
improvements in patient reported adherence, utilisation of rescue packs, quality of
life and a reduction in routine general practitioner (GP) visits were identified. The
intervention cost was estimated to be off-set by reductions in the use of other NHS
services (GP and accident and emergency visits and hospital admissions).
Conclusions Results suggest that the service improved patient medicine taking
behaviours and that it was cost-effective.
Introduction
Chronic obstructive pulmonary disease (COPD) is normally
a progressive disease, which is most frequently associated
with smoking.[1] Currently the fourth biggest killer world-
wide, it will be third by 2020.[2] COPD has 5-year survival
rates of 78% for men and 72% for women with mild disease,
which reduces to 30% and 24% respectively in severe
disease.[3] It is estimated that up to a quarter of adults over the
age of 40 have some form of mild airway obstruction,[4] and
this correlates closely to the proportion of the population
known to smoke. Within the UK the cost of COPD to the
National Health Service (NHS) was estimated to be between
£805M and £870M in 2009,[5] and this is largely due the cost of
treating and managing the disease and hospital bed days asso-
ciated with exacerbations of the condition.
COPD presents as a limitation of airflow that is not fully
reversible and results from fibrosis and loss of elasticity of
small airways, destruction of alveoli as they eventually lose
their ability to repair and the permanent production of
mucus as a non-specific immune response.[6] Clinical diagno-
sis of COPD is made on the basis of shortness of breath
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(dyspnoea), chronic sputum production or cough, and
history of exposure to a known risk factor. Once diagnosed,
the severity is then based on the extent of airflow obstruction
(GOLD Standards): stage 1 (mild, forced expiratory volume
in 1 s (FEV1) ≥ 80% of predicted), stage 2 (moderate, FEV1
50–80% of predicted), stage 3 (severe, FEV1 30–50% of pre-
dicted) and stage 4 (very severe, FEV1 <30% of predicted),
and treatment is prescribed accordingly.[1]
Smoking cessation is usually the first stage in the manage-
ment of COPD, and following this, yearly influenza vaccina-
tions should be offered due to the reduced ability of their
lungs to respond to infections.[7] All COPD patients should be
prescribed inhaled short-acting beta agonists or muscarinic
antagonists to increase lung capacity. As FEV worsens, then
long-acting beta-agonists and muscarinic antagonists are
introduced as combination therapy with the final option
being to introduce inhaled corticosteroids.[7] The effective-
ness of this approach is determined by the patient’s ability to
use an inhaler correctly[8] and by their willingness to use it as
agreed with the prescriber.[9] Devices such as the In-Check
Dial (Clement Clarke International, Harlow, UK) are avail-
able to ensure that the type of inhaler selected for a patient is
appropriate for their pulmonary function.[10] Evidence sug-
gests that interventions to improve patient use of their inhal-
ers can significantly improve the management and care of
patients with COPD.[11] It has been recommended in the UK
that the inhaler technique and medication for all patients
with COPD are reviewed on a yearly basis[12] and that a COPD
assessment test (CAT)[13] be used to measure any changes
resulting from this.
Severe exacerbations of COPD are one of the main causes
of hospital bed days,[14] and hence guidance suggests that
patients who frequently experience exacerbations should be
given antibiotics and oral corticosteroids to be kept at home
(rescue packs) to prevent deterioration.[7]
With medication central to the effective management of
COPD and smoking cessation the first part of the process, the
community pharmacist is ideally located to undertake a more
proactive role in the care of such patients. Community phar-
macists frequently provide smoking cessation services or can
signpost patients to them. Researchers have reported that
community pharmacy services for patients with COPD
should focus on drug adherence, influenza vaccination,
smoking cessation and inhaler technique.[15]
A small pilot study reported in Canada in 2012 to test
whether community pharmacists can contribute to the man-
agement of patients with COPD and utilising many of the
approaches described by Mehuys[15] demonstrated patient
and physician acceptability and that appropriate recommen-
dations can be made to improve therapy.[16] The significant
time required to deliver the service was identified as a barrier,
and consequently appropriate funding was stated to be
required.[16]
One large-scale controlled service evaluation based on 212
Dutch community pharmacies (107 intervention and 105
control) where 3757 patients received a comprehensive inter-
vention to improve sup-optimal drug use demonstrated that
such a service reduced the need for steroids and antibiotics in
the intervention arm, reduced medicine wastage and
improved selection of inhaler device.[17] A single-blind,
randomised controlled study conducted in 170 community
pharmacies within Belgium over a 3-month period with 734
patients demonstrated improvements in adherence, inhala-
tion score and reductions in hospitalisation.[18]
Within the UK there is growing evidence for community
pharmacy–based interventions to improve medicines
support for patients with COPD[19,20]; however, no evalu-
ations have effectively captured costs or effect on quality of
life. Within a budget-constrained health system, it is no
longer sufficient to demonstrate the effectiveness of a service
and although an outpatient hospital pharmacy–based COPD
management service has been demonstrated to be cost-
effective,[21] there is no similar evidence for such a community
pharmacy–based service.
The aim of this paper is therefore to describe the effective-
ness of a community pharmacy–based COPD service deliv-
ered from a wide variety of community pharmacies and to
provide an initial indication as to the cost-effectiveness of the
intervention.
Method
Following advice from the Nottingham NHS Research Ethics
Committee, the project was deemed a service evaluation, and
therefore formal ethical approval was not required. Written
confirmation supporting this decision was provided by UEA
ethical committee. The COPD service was delivered from
September 2012 to June 2013 and located in Boots UK,
Co-operative, Lloyds and Rowland pharmacies.
Pharmacist recruitment and training
All 34 pharmacies belonging to the four companies in the
Wirral in the North West of England provided the service and
were included in the evaluation. One pharmacist from each
pharmacy attended a 1-day training course, which they were
then responsible for cascading to the remaining colleagues in
store.All pharmacy staff involved in service delivery were pro-
vided with distance learning materials for pre-reading; com-
pletion of which was compulsory.
Patient identification and recruitment
A variety of methods was utilised to identify patients suitable
for the service. Leaflets were located in pharmacies to enable
patients to self-present. Potentially suitable patients were
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identified through pharmacy medication records, and the
service was then discussed with them when they presented for
their repeat prescription. Patients who were interested were
given an information form to take away and consider. Addi-
tionally, the service was promoted to relevant primary
healthcare professionals local to the pharmacy who subse-
quently provided potentially appropriate patients with a
referral to the service.
Presenting patients were asked to confirm their diagnosis
and where there was any uncertainty, the pharmacist was
expected to confirm with the GP practice prior to recruiting.
All patients completed a consent form prior to participation.
Only patients presenting within the first 10 weeks of the
service initiation were included within the service evaluation.
COPD service
The service involved supporting patients to stop smoking (if
appropriate), helping patients to recognise symptoms of
exacerbations and enabling them to respond, e.g. through
rescue packs. The service aimed to improve medicines adher-
ence, through the provision of advice on how to use inhalers
and ensuring that patients were using the most appropriate
inhaler device. General lifestyle advice was also provided
where necessary.
Consented patients were screened, and the following infor-
mation obtained:
• Patient demographics
• CAT score[13]
• Medical Research Council dyspnoea score[22]
• Appropriateness of current inhaler (In-Check Dial meter
recommendation).
The pharmacist discussed the initial assessment with the
patient and provided the following interventions as deemed
necessary:
• Medication counselling
• Lifestyle advice
• Stop smoking service (if patients were receptive to it)
or signposting to such a service if not provided in the
pharmacy
• Referral letter to their GP to obtain a COPD rescue pack.
Where recommendations were identified, these were also
communicated to the patient’s GP. An action plan was agreed
with each patient and monitored in follow-up patient visits
that were arranged at the patient’s convenience; usually this
coincided with collection of regular prescriptions.
Data collection
Age, gender, height, weight, body mass index and smoking
status (patient reported) were collated for each recruited
patient. Activities undertaken within the initial consultation
were recorded.
At baseline the following information was additionally
obtained:
• EQ-5D (T) (quality of life)[23]
• Morisky assessment of adherence (8 = high adherence,
6 < 8 = moderate adherence, < 6 = low adherence).[24]
EQ-5D was chosen as the preferred measure of quality of
life as it is recommended by the National Institute for Health
and Care Excellence (NICE), which is the UK Government
body for recommending which health interventions can be
afforded.[25]
Participants were also asked at (1) baseline (recall period:
previous 6 months) and (2) every subsequent visit (recall
period: since their last visit) to report the number of the fol-
lowing items of resource use:
• routine GP visits for COPD;
• exacerbations treated by GP;
• hospital admissions for severe COPD exacerbations (and
associated number of days per admission, if applicable);
• other hospital admissions (and associated number of days
per admission, if applicable);
• A&E visits;
• rescue packs obtained; and
• days off sick.
Data analysis
To be included in the final analysis, each patient was required
to have attended:
• an initial assessment where all baseline data were measured;
and
• at least one follow-up visit at 6 months ± 30 days.
The demographics of those who were included in the final
analysis were compared with those who were excluded (due
to incomplete data) to assess for selection bias.
Service impact
For the main analysis, once mean values had been derived for
each parameter before and after the pharmacy service inter-
vention, mean differences and associated confidence intervals
(CIs) were generated. The underlying assumption was that
the sampling distributions of the mean estimates were nor-
mally distributed (though the distributions of many of the
parameters were skewed). The assumption of a normal sam-
pling distribution was made by applying the central limit
theorem that requires that samples in question should have
n > 30 patients. CIs associated with the estimate of mean
change that did not cross zero were deemed to be statistically
significant. The impact of potential confounding, bias and
regression to the mean were not explored in the analysis.
Economic evaluation
Costs (see Table 1) were assigned to each of the aforemen-
tioned items of resource use, where these were estimated
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at 2011/2012 financial year levels. Total cost of the interven-
tion was estimated by summing the cost of the consulta-
tions, training and equipment. Total other NHS costs were
estimated by summing the costs associated with each of the
self-report items of resource use, apart from days off sick.
Total NHS costs were estimated by summing the interven-
tion cost and total other NHS costs. Total societal costs were
estimated by summing the lost productivity (estimated
from days reported off sick) and total NHS costs. Mean
costs over the 6-month pre-intervention period and the
6-month follow-up period were subsequently estimated for
each of these total costs, and the mean difference was esti-
mated by subtracting the mean 6-month pre-intervention
cost from the mean 6-month follow-up cost. This difference
provides an estimate of the change in cost associated with
the intervention.
EQ-5D scores were converted into a utility score (death is
equal to 0 and full health to 1).[23] The area under the curve
method[26] was used to estimate the change in quality adjusted
life year (QALY) score between the baseline and follow-up.
This difference provides an estimate of the QALY change
associated with the intervention.
The intervention would be estimated to dominate
no intervention if the mean estimated change in cost
associated with the intervention was negative and the
mean estimated QALY change associated with the inter-
vention was positive (i.e. the intervention was estimated
to be less costly overall and more effective). Alternatively, the
incremental cost-effectiveness ratio would be calculated
(mean change in cost/mean QALY change)[25] and com-
pared with the threshold (λ) of £20,000 per QALY.[25]
Based on the cost-effectiveness acceptability curve
(CEAC),[27] we also report the estimated probability of the
intervention being cost-effective at the λ of £20,000 per
QALY.
Results
Thirty-four community pharmacies from the Wirral area in
England participated in the study. Three hundred six patients
were registered for the service of which 156 (51.0%) patients
were male and 117 (38.2%) were smokers.
One hundred seven (35.0%) patients dropped out during
the 6-month service with the main following reasons pro-
vided: 23 (7.5%) did not want to bother again, 14 (4.6%)
became housebound, nine (2.9%) did not have any time, nine
(2.9%) died, eight (2.6%) unknown and eight (2.6%) were no
longer customer at the pharmacy.
One hundred ninety eight (99.5%) of initial visits involved
an inhaler check, 136 (68.3%) resulted in a change in inhaler
technique, 72 (36.3%) resulted in smoking cessation advice,
181 (91.0%) in healthy lung advice, 197 (99.0%) flu advice
and 194 (97.5%) were subsequently recorded as having had a
flu vaccination. Fifty-eight (42.3%) patients received advice
on physical activity, 53 (38.7%) received advice on diet and
nutrition, 26 (19.0%) weight management and 20 (14.6%) on
alcohol use. Twenty-five (18.2%) of patients were referred to
the GP following pharmacist consultation.
Data were available for comparison at baseline and 6
months for 137 patients (within the ± 30 days timeframes).
Previous levels of resource use were also reported at this point
by the 137 patients. Follow-up EQ-5D scores were also avail-
able for the 137 patients, though only 92 patients reported the
resource use and EQ-5D data at the same visit. The 47.5% of
the final cohort for analysis were male compared with 54.2%
in the sample not used. The mean (standard deviation) age of
the final cohort was 69 (8.4) compared with 68 (10.9) in the
sample not used.
Table 2 provides a comparison of patient characteristics
and service outcomes at baseline and 6 months. It can be
seen that the COPD assessment test score improved over the
6 months, as did patient reported adherence. In total, there
was a 4.1% decrease in the percentage of patients smoking
over the 6-month duration of the evaluation. In patients
who were smoking at baseline, this represented a quit rate of
13.85%.
A description of the resource use associated with the com-
ponent parts of the intervention is given in Table 3, where the
mean intervention cost was estimated to be £63.62 per par-
ticipant. Table 3 details that all 306 participants had an initial
consultation and that there were a subsequent 742 monthly
consultations and 423 quarterly consultations across all
patients. The estimated length of each of these consultations
is also given. The main purpose of these consultations was to
reinforce what had previously been discussed and to answer
any questions participants may have had.
The levels of resource use reported by the 137 patients are
summarised in Table 4, where it can be seen that the mean
levels of resource are all lower in the 6-month follow-up
Table 1 Unit costs attached to different items of resource use, with
associated source
Item
Estimated
unit cost
Pharmacist (non-patient contact time)* £50.00
Pharmacist (patient contact time)* £63.00
Health care assistant (cost per hour of employment) £12.50
GP visit* £43.00
Hospital admission (cost per day)† £254.00
Day case (weighted average of all procedures)† £680.70
A&E visit (not admitted cost)* £112.00
Rescue pack# £7.00
Day off work (excluding over time) ‡ £110.70
*Taken from Curtis.[34] †Taken from the National Schedule of Reference
Costs.[35] #Estimate based on Schomberg et al.[36] ‡Based on the Office for
National Statistics Annual Survey of Hours and Earnings.[37]
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period compared with pre-intervention, with the exception
of the rescue packs.
Overall, the mean (per patient) total other NHS costs pre-
intervention were higher compared with that in the 6-month
follow-up period (see Table 3), as was the mean total NHS
and societal costs (when the intervention costs and lost prod-
uctivity costs, respectively, were included). Thus, the mean
cost of the intervention was estimated to be off-set by reduc-
tions in other items of resource use – the overall mean per
participant estimated change in cost associated with the
intervention was estimated to be a cost saving of £87.66 (95%
CI £148.91 increase to £323.96 saving) (based on total NHS
costs) and £94.12 (95% CI £140.21 increase to £331.88
saving) (based on total societal costs).
The mean baseline and follow-up EQ-5D scores were 0.615
and 0.644, respectively. This equates to a mean change in
EQ-5D score of 0.029 (95% CI 0.005 to 0.052) and resulted in
an estimated change in QALY of 0.008 (95% CI 0.000 to
0.017) at follow-up (mean time = 201 days).
As the intervention was estimated to be associated with a
cost saving (from both an NHS and a societal perspective)
and a QALY gain, the intervention was estimated to dominate
no intervention. According the CEAC, the estimated prob-
ability of the intervention being cost-effective at the λ of
£20,000 per QALY was 96.7% and 97.2%, respectively.
Discussion
COPD is a progressive degenerative disease, and conse-
quently ongoing reductions in quality of life scores and meas-
urements related to the management of the condition are
expected over time. The significant improvement in quality of
life and reduction in the COPD assessment test score suggests
that the community pharmacy–led COPD service can
provide positive patient outcomes. The improvement in
patient-reported adherence may explain some of the effect
seen, as may the increase in use of rescue packs and the reduc-
tion in the number of smokers. Interestingly, a reduction in
overall NHS costs was also identified that suggests that the
service is likely to represent good value for money and be con-
sidered to be cost-effective in relation to NICE criteria.[25]
These data however have to be viewed with some caution as
they are based on a before-and-after study with no control
group for comparison. Consequently, it is difficult to differ-
entiate differences that may have occurred without the inter-
vention from those which occurred as a result of the
intervention. Knowledge of the nature of the intervention is
used to enable the reader to determine the likelihood of
resultant changes from the pharmacy service. Additionally it
should be noted that participants received the initial inter-
vention contact between September 18, 2012 and November
26, 2012. As such, the follow-up period was concentrated
more in the winter months (when the condition would be
expected to be worse) than the pre-intervention period (to
which it was compared). Also, though resource use informa-
tion was not always requested at precisely 6 months
Table 2 Comparison of outcome measures at baseline and six months
Parameter (n = 137) n Measure Baseline Follow-up Difference (95% CI) P
Proportion smokers 98 No. (%) 30 (30.6) 26 (26.5) −4.1% 0.219#
CAT score 137 Mean 20.810 19.955 −0.869 (−0.099, 1.836) 0.078*
Medical Research Council dyspnoea 137 Mean 2.854 2.880 0.044 (−0.090, 0.186) 0.542*
Adherence 137 Mean 7.073 7.6369 0.564 (0.304, 0.824) < 0.001*
#McNemar’s test. *Paired samples t-test.
Table 3 Intervention costs
Component part
Resources cost (unit cost), participant
costing
Mean cost
(£ per
participant)
Training (receipt) Pre-course e-learning (16 pharmacist
hours) plus training course (2 h for
pharmacist trainer and 8 h for
pharmacists trained) plus 1 h of
cascade training (pharmacist and
three healthcare assistants)
(pharmacists £50 per hour*,
healthcare assistant £12.50 per
hour), divided across all n = 306
participants
3.23
Initial consultation 20-min patient contact time with
pharmacist (£63 per hour*),
n = 306 participants attended
21.00
Monthly review 7-min patient contact time with
pharmacist (£63 per hour*) and
3 min of healthcare assistant time
(£12.50 per hour†), n = 742
occurred.
19.34
Quarterly review 11-min patient contact time with
pharmacist (£63 per hour*) and
4 min of healthcare assistant time
(£12.50 per hour†), n = 423
occurred.
17.12
Equipment In check (£49.55) and other services
materials (£75.00), divided across
all n = 306 participants
1.63
Total 63.62
†estimated within study costs; *Taken from Curtis.[34]
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post-intervention, the mean follow-up time (and time over
which people would be asked to report levels of resource use)
was longer than 6 months (mean time was 190 days post
initial contact). A further potential weakness is that though a
wide range of NHS services were asked about (see Table 4)
information was not requested on all NHS and personal
social service items. Though the methods used to collect
resource use data are in line with many other economic
studies,[28] it should also be noted that the self-report resource
use data were not compared with resource use data in medical
records.
Furthermore, although relatively large numbers of patients
were recruited in a relatively short period of time, one-third
did not complete the service. This attrition rate is higher than
that reported in similar studies,[15] studies to improve self-
management in COPD patients[29] and for interventions not
designed to test new treatments.[30] Further in-depth explora-
tion of patient withdrawal may help to improve service
acceptability and perceived value. The recruitment rate of
approximately one patient per pharmacy per week in its first
10 weeks of initiation (with a minimum rate of 0.4 and
maximum rate of 1.9) is relatively high for a specific condi-
tion and detailed inclusion criteria,[18,31,32] suggesting that
recruitment to the service would not be difficult if the service
was extended.
Validated and nationally recognised tools were used for
data collection purposes and therefore the available results
can generally be trusted as accurate reflections of patient
status. However, tools such as Morisky are known to have
poor specificity[24] as they rely on patients responding hon-
estly to surveys from healthcare professionals whom they may
not wish to admit deviant behaviour to. Although a second
measure of adherence would have improved validity, it is a
process measure and was used as a possible explanation for
changes in clinical outcomes. Statistical analyses did not
explore the potential impact of confounding, bias, or regres-
sion to the mean. That said, pharmacy data were only avail-
able for a 6-month period; over a longer time horizon, greater
cost savings and improvements in patient quality of life may
be possible.
Even with a diminished sample size, significant changes in
patient outcomes were seen. With a mean score nearing 8 on
the Morisky scale, it can be seen that the majority of patients
reported very high adherence at the end of the 6-month
period. The proportion of patients who had low and medium
adherence at beginning reduced, whereas patients reporting
high adherence increased. Although this improvement could
also be due to social desirability bias, i.e. patients knowing
that the pharmacist expects their adherence to improve may
rate it higher to please the researchers, it is unlikely to have a
large effect as the same bias may have been present when the
service was first introduced and the scores were originally
obtained. The use of the In-Check Dial is known to improve
inhaler selection for patients with COPD,[10] and therefore the
improvement in adherence may partially result from receiv-
ing greater benefit from treatment. It may also be due to the
pharmacist explaining the importance of the medicines and
due to patient concerns regarding side effects being allayed.
Elements of the pharmacy service that were not directly
measured included the provision of comprehensive advice on
weight management, diet and alcohol. These additional inter-
ventions will provide some added value to the service that
may not have been directly captured within the 6-month
window of the evaluation.
Table 4 Per participant mean (range) levels of resource use and associated costs for n = 137
Levels of resource use Mean cost (£)
Item Pre-intervention
6-month
follow-up Difference Pre-intervention
6-month
follow-up Difference
Routine GP visits for COPD 1.40 0.90 –0.50 £60.26 £38.61 –£21.66
Exacerbations treated by GP 1.12 1.10 –0.01 £48.02 £47.39 –£0.63
Hospital admissions: COPD exacerbations 0.12 0.07 –0.06
Days per admission (average) 4.18 5.14
Combined total (days in hospital) 0.04 0.02 –0.02 £177.39 £116.21 –£61.18
Hospital admissions: other 0.31 0.23 –0.07
Days per admission (average) 3.08 2.72
Combined total (days in hospital) 0.94 0.64 –0.31 £282.33 £201.64 –£80.68
A&E visits 0.09 0.05 –0.04 £10.63 £4.91 –£5.72
Rescue packs issued 0.42 0.66 0.24 £2.96 £4.65 £1.69
Lost productivity (based on days off) 0.25 0.19 –0.04 £27.47 £21.01 –£6.46
Total other NHS costs £581.59 £413.41 –£168.19
Intervention costs £80.53 £80.53
Total NHS costs £581.59 £493.94 –£87.66
Total societal costs £609.07 £514.95 –£94.12
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A substantially higher proportion of patients within the
analysis cohort received flu vaccinations (97.5%) compared
with the reported general uptake rate of 75.4% in the Wirral
area,[33] and again the benefit of this has not been extrapolated
in either the measured impacts or estimated costs.
The signposting and referral to the GP resulted in the pre-
scribing of rescue packs. With GPs responsible for the cost of
acute hospital admissions, the proactive nature of this inter-
vention, which is designed to reduce GP call out and hospi-
talisation, should have been well received. Unfortunately, data
on GP opinions of the service were not collated.
This service represents a unique collaboration by the large
companies that represent just under half of community phar-
macies in the UK. The service was set up within 9 months of
initial concept and demonstrates that collaborative working
is possible and may be necessary if arguments are to be made
to government for additional funding for more patient facing
services. The fact that recruitment was undertaken efficiently
and improvements in patient parameters were seen suggests
that this service is being delivered effectively and to standard
quality.
The service was estimated to be associated with a mean cost
saving (from both NHS and societal perspectives) and a mean
QALY gain. This suggests that the service was cost-effective,
though due to the before-and-after nature of the analysis,
these results should be treated with caution.
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